ACTIVE  

• NIH R01     HL139963     (Ishikawa)            12/15/2017 – 11/30/2022          Percutaneous Left Ventricular Unloading for Cardiogenic Shock: Beyond Acute Hemodynamic Support
• Abiomed   Inc.        (Ishikawa)                       03/01/2016 – 12/31/2025         Improving the gene transduction efficacy of intracoronary delivery using an Impella     Role (PI)
• Cardiac RSK3 inhibitors (Ishikawa)             9/30/2021-9/29/2022             AAV-RBD gene therapy in a pig model of myocardial infarction
• NIH       R01HL148786 (Sahoo)                    07/01/2019 – 06/30/2024        AAV-Exosomes: Escaping Neutralizing Antibody and Enhancing Delivery   Role (Co-I)
• NIH NHLBI GTRP RSA 2035   (Ishikawa)                                                         Preclinical Vector Production “Improving Cardiac AAV Gene Transduction Using Intracoronary Delivery”

• T32 Research Fellowship (Marvopoulos)         06/28/2021 – 06/27/2024
• ACURE Research Fellowship Grant (Sakata)  07/01/2021 – 06/30/2022

Completed

• NIH/NHLBI   1R01HL130423-01 (Ishikawa/Kovacic)         01/25/2016 – 12/31/2021         Toward Therapeutic Manipulation of Endothelial to Mesenchymal Transition.          Role (Co-PI)
• NIH/NHLBI  1R01HL135093 (Fish/Kovacic)    12/01/2016 – 11/30/2021           Therapeutic Mechanisms of Cardiac Progenitors in Ischemic Cardiomyopathy       Role (Co-I)
• AHA-SDG      17SDG33410873     (Ishikawa)    01/01/2017 – 12/31/2019            Mechanistic and Therapeutic Roles of miRNAs in Left Ventricular Remodeling and Heart Failure        Role (PI)
• NIH       R01HL131404 (Hajjar/Weber)               07/01/2016 – 06/30/2020          Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy       Role (Co-I)
• Cardiac RSK3 Inhibitors, LLC (Fish)                    02/06/2019 – 02/05/2020         Gene Therapy for Cardiac Remodeling
• T32 Research Fellowship (Mazurek)                  09/22/2020 – 09/21/2021